The diagnosis and management of prosthetic joint infections

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue SUPPL. 3, 2010, Pages

  Moran, E ^a,b   Byren, I ^a,b   Atkins, B L ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

Joint revision; Outpatient parenteral antimicrobial therapy

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FUSIDATE SODIUM; LINEZOLID; MEROPENEM; RIFAMPICIN; TEICOPLANIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD ANALYSIS; BONE GRAFT; CLINICAL FEATURE; DEBRIDEMENT; DIAGNOSTIC ACCURACY; DRUG ADMINISTRATION ROUTE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INFECTIOUS DISEASE MEDICINE; JOINT PROSTHESIS; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGY; NONHUMAN; NURSE; OCCUPATIONAL THERAPIST; ORTHOPEDIC SURGERY; PATHOGENESIS; PHYSIOTHERAPIST; PLASTIC SURGERY; PROSTHESIS INFECTION; RADIOLOGY; RECOMMENDED DRUG DOSE; RISK FACTOR; SURGICAL TECHNIQUE;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; EARLY DIAGNOSIS; HUMANS; MALE; OSTEOARTHRITIS; PROSTHESIS-RELATED INFECTIONS; SURGICAL PROCEDURES, OPERATIVE;

EID: 77957696699     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq305     Document Type: Article

References (67)

1. 5th Report of the Mandatory Surveillance of Surgical Site Infection in Orthopaedic Surgery. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259151994683 (9 March 2010, date last accessed).
2. Darouiche R. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350: 1422-9.
3. Zimmerli W, Trampuz A, Ochsner P. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
4. Gristina A, Naylor P, Myrvik Q. Infections from biomaterials and implants: a race for the surface. Med Prog Technol 1988; 14: 205-24.
5. Trampuz A, Zimmerli W. Prosthetic joint infections: update in diagnosis and treatment. Swiss Med Wkly 2005; 135: 243-51.
6. Berbari E, Hanssen A, Duffy M et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27: 1247-54.
7. Wilson M, Kelley K, Thornhill T. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixtyseven cases. J Bone Joint Surg Am 1990; 72: 878-83.
8. Zimmerli W. Infection and musculoskeletal conditions: prostheticjoint-associated infections. Best Pract Res Clin Rheumatol 2006; 20: 1045-63.
9. Ainscow D, Denham R. The risk of haematogenous infection in total joint replacements. J Bone Joint Surg Br 1984; 66: 580-2.
10. Murdoch D, Roberts S, Fowler VJ Jr et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 2001; 32: 647-9.
11. Moran E, Masters S, Berendt A et al. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect 2007; 55: 1-7.
12. Stefánsdóttir A, Johansson D, Knutson K et al. Microbiology of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis 2009; 41: 831-40.
13. Fink B, Makowiak C, Fuerst M et al. The value of synovial biopsy, joint aspiration and C-reactive protein in the diagnosis of late peri-prosthetic infection of total knee replacements. J Bone Joint Surg Br 2008; 90: 874-8.
14. Palestro CJ, Love C, Tronco GG et al. Combined labeled leukocyte and technetium 99m sulfur colloid bone marrow imaging for diagnosing musculoskeletal infection. Radiographics 2006; 26: 859-70.
15. Berbari E, Marculescu C, Sia I et al. Culture-negative prosthetic joint infection. Clin Infect Dis 2007; 45: 1113-9.
16. Health Protection Agency 2009. Investigation of prosthetic joint infection samples. National Standard Methods BSOP 44 Issue 1.1. http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop44.pdf (5 July 2010, date last accessed).
17. Atkins B, Athanasou N, Deeks J et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS Collaborative Study Group. J Clin Microbiol 1998; 36: 2932-9.
18. Pandey R, Berendt A, Athanasou N. Histological and microbiological findings in non-infected and infected revision arthroplasty tissues. The OSIRIS Collaborative Study Group. Oxford Skeletal Infection Research and Intervention Service. Arch Orthop Trauma Surg 2000; 120: 570-4.
19. Tohtz S, Müller M, Morawietz L et al. Validity of frozen sections for analysis of periprosthetic loosening membranes. Clin Orthop Relat Res 2010; 468: 762-8.
20. Francés Borrego A, Martínez F, Cebrian Parra J et al. Diagnosis of infection in hip and knee revision surgery: intraoperative frozen section analysis. Int Orthop 2007; 31: 33-7.
21. Athanasou N, Pandey R, de Steiger R et al. Diagnosis of infection by frozen section during revision arthroplasty. J Bone Joint Surg Br 1995; 77: 28-33.
22. Schäfer P, Fink B, Sandow D et al. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis 2008; 47: 1403-9.
23. Trampuz A, Piper K, Jacobson M et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007; 357: 654-63.
24. Fenollar F, Roux V, Stein A et al. Analysis of 525 samples to determine the usefulness of PCR amplification and sequencing of the 16S rRNA gene for diagnosis of bone and joint infections. J Clin Microbiol 2006; 44: 1018-28.
25. Dixon P, Parish E, Cross M. Arthroscopic debridement in the treatment of the infected total knee replacement. J Bone Joint Surg Br 2004; 86: 39-42.
26. Byren I, Bejon P, Atkins B et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 2009; 63: 1264-71.
27. Marculescu C, Berbari E, Hanssen A et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis 2006; 42: 471-8.
28. Berbari E, Osmon D, Duffy M et al. Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis 2006; 42: 216-23.
29. Hsieh P, Lee M, Hsu K et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009; 49: 1036-43.
30. Cui Q, Mihalko W, Shields J et al. Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. J Bone Joint Surg Am 2007; 89: 871-82.
31. Stockley I, Mockford B, Hoad-Reddick A et al. The use of two-stage exchange arthroplasty with depot antibiotics in the absence of long-term antibiotic therapy in infected total hip replacement. J Bone Joint Surg Br 2008; 90: 145-8.
32. Bejon P, Berendt A, Atkins B et al. Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology. J Antimicrob Chemother 2010; 65: 569-75.
33. Harvey D, Townsend R, Kerry R et al. Prosthetic joint infection. Treatment without long courses of systemic antibiotics. BMJ 2009; 339: b3052.
34. McDonald D, Fitzgerald RJ, Ilstrup D. Two-stage reconstruction of a total hip arthroplasty because of infection. J Bone Joint Surg Am 1989; 71: 828-34.
35. Raut V, Siney P, Wroblewski B. One-stage revision of total hip arthroplasty for deep infection. Long-term followup. Clin Orthop Relat Res 1995; 321: 202-7.
36. Johannsson B, Taylor J, Clark C et al. Treatment approaches to prosthetic joint infections: results of an Emerging Infections Network survey. Diagn Microbiol Infect Dis 2010; 66: 16-23.
37. Stengel D, Bauwens K, Sehouli J et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001; 1: 175-88.
38. Dunne N, Hill J, McAfee P et al. Incorporation of large amounts of gentamicin sulphate into acrylic bone cement: effect on handling and mechanical properties, antibiotic release, and biofilm formation. Proc Inst Mech Eng H 2008; 222: 355-65.
39. Hsieh P, Huang K, Tai C. Liquid gentamicin in bone cement spacers: in vivo antibiotic release and systemic safety in two-stage revision of infected hip arthroplasty. J Trauma 2009; 66: 804-8.
40. Hsieh P, Chang Y, Chen S et al. High concentration and bioactivity of vancomycin and aztreonam eluted from Simplex cement spacers in two-stage revision of infected hip implants: a study of 46 patients at an average follow-up of 107 days. J Orthop Res 2006; 24: 1615-21.
41. Masri B, Duncan C, Beauchamp C. Long-term elution of antibiotics from bone-cement: an in vivo study using the prosthesis of antibiotic-loaded acrylic cement (PROSTALAC) system. J Arthroplasty 1998; 13: 331-8.
42. Hsieh P, Huang K, Lee P et al. Two-stage revision of infected hip arthroplasty using an antibiotic-loaded spacer: retrospective comparison between short-term and prolonged antibiotic therapy. J Antimicrob Chemother 2009; 64: 392-7.
43. Hoad-Reddick D, Evans C, Norman P et al. Is there a role for extended antibiotic therapy in a two-stage revision of the infected knee arthroplasty? J Bone Joint Surg Br 2005; 87: 171-4.
44. Matthews PC, Berendt AR, McNally MA et al. Diagnosis and management of prosthetic joint infection. BMJ 2009; 338: b1773.
45. Jämsen E, Stogiannidis I, Malmivaara A et al. Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop 2009; 80: 67-77.
46. Esposito S, Leone S, Noviello S et al. Outpatient parenteral antibiotic therapy for bone and joint infections: an Italian multicenter study. J Chemother 2007; 19: 417-22.
47. Upton A, Ellis-Pegler R, Woodhouse A. Outpatient Parenteral Antimicrobial Therapy (OPAT): a review of experience at Auckland Hospital. N Z Med J 2004; 117: U1020.
48. Standardized methods for implementation of OPAT services in the UK. http://www.bethereglobal.com/opat-uk/index.html (9 April 2010, date last accessed).
49. Samuel JR, Gould FK. Prosthetic joint infections: single versus combination therapy. J Antimicrob Chemother 2010; 65: 18-23.
50. Zimmerli W, Widmer A, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-41.
51. Widmer A, Frei R, Rajacic Z et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162: 96-102.
52. Aboltins C, Page M, Buising K et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13: 586-91.
53. Baldoni D, Haschke M, Rajacic Z et al. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 2009; 53: 1142-8.
54. John A, Baldoni D, Haschke M et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009; 53: 2719-24.
55. Cepeda JA, Whitehouse T, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53: 345-55.
56. Schaad HJ, Chuard C, Vaudaux P et al. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38: 1703-10.
57. Matthews P, Taylor A, Byren I et al. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect 2007; 55: 408-13.
58. Kaka A, Rueda A, Shelburne Sr et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 680-3.
59. Grim S, Rapp R, Martin C et al. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25: 253-64.
60. Stein A, Bataille J, Drancourt M et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-91.
61. Adra M, Lawrence K. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004; 38: 338-41.
62. Rand K, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-2.
63. Brouqui P, Rousseau M, Stein A et al. Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob Agents Chemother 1995; 39: 2423-5.
64. Martínez-Pastor J, Muñoz-Mahamud E, Vilchez F et al. Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother 2009; 53: 4772-7.
65. Saving Lives. High Impact Intervention No 4: Care bundle to prevent surgical site infection. UK Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_078134 (6 April 2010, date last accessed).
66. Screening elective patients for MRSA: Frequently asked questions. http://www.dh.gov.uk/en/Publichealth/Healthprotection/Healthcareassociated infection/DH_094120 (28 March 2010, date last accessed).
67. Berbari E, Osmon D, Carr A et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis 2010; 50: 8-16.